rxstat › Classes › Antimigraine Preparations

Antimigraine Preparations: shortage status in Canada

5 of the 9 antimigraine preparations rxstat tracks are currently in shortage in Canada. When one drug in a class is short, demand often shifts to its alternatives, so related drugs can tighten too; each page below shows which manufacturers are affected and the latest recovery estimates.

Almotriptan (Axert) Partial shortage 1 of 10 reported products affected Eletriptan (Relpax) Partial shortage 2 of 18 reported products affected · est. return Sep 29, 2026 Pizotifen (Sandomigran Ds) Partial shortage 1 of 1 reported products affected · est. return Jul 31, 2026 Rizatriptan (Maxalt Rpd) Partial shortage 8 of 37 reported products affected · est. return Dec 31, 2026 Zolmitriptan (Zomig Rapimelt) Partial shortage 10 of 28 reported products affected · est. return Jan 3, 2028 Sumatriptan (Imitrex) Shortage anticipated 0 of 23 reported products affected Dihydroergotamine No current shortage Frovatriptan (Frova) No current shortage Naratriptan (Amerge) No current shortage

Guides: what to do when your medication is in shortage · how to read these statuses

Class groupings follow the WHO ATC classification in Health Canada's reports. Data reflects manufacturer mandatory filings; see methodology.